Skip to main content

Advertisement

Fig. 2 | BMC Infectious Diseases

Fig. 2

From: The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study

Fig. 2

Anti-Vacc-C5-specific antibodies (AB) in serum. a AB levels for the total cohort at week 1 (baseline), 6 (after initial immunisation), 15 (after1st boost) and 26 (after 2nd boost, end of study). Data are given as medians, interquartile and overall ranges. The change from baseline to end of study is indicated (Wilcoxon matched pairs test). b AB levels for the three dose groups at week 1, 6, 15 and 26. LD = low, MD = median and HD = high dose. Data are given as medians, interquartile and overall ranges. Changes within each dose group with p-values less than 0.10 are indicated (Wilcoxon matched pairs test)

Back to article page